Kornimate/medical-research-clean huggingface dataset:
radiofrequency ablation combined with chemotherapy for pulmonary tumors

Conditions: NSCLC; Pulmonary Metastases

Summary: the purpose of this study is to assess short and long term outcomes after radiofrequency ablation (rfa) combined with chemotherapy for pulmonary malignancies in patients who are not candidates for surgical resection. this study will evaluate the efficacy of rfa combined with chemotherapy for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (qol).

percutaneous image-guided rfa is a minimally invasive technique used to treat solid tumours. because of its ability to produce large volumes of coagulation necrosis in a controlled fashion, this technique has gained acceptance as a viable therapeutic option for unresectable liver malignancies. recently, rfa has been proposed as a viable option for the treatment of pulmonary malignancies. experimental studies in animal tumor models have confirmed the effectiveness of rfa in the destruction of experimentally-induced pulmonary malignancies. pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response. we designed a prospective clinical trial aimed at assessing feasibility, safety and effectiveness of rfa combined with chemotherapy in the treatment of lung malignancies.

Eligibility criteria:
inclusion criteria: * adult (\> 18 years) male or female patient * patient has biopsy-proven nsclc or lung metastasis * patient has been rejected for surgery and has been considered unfit for radiation therapy * each 6 cm or smaller in greatest diameter of tumor, by ct scan * tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart * tumors are accessible by percutaneous route * patient has eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * patient has platelet count \> 100 x 109 /l and international normalized ratio ≤ 1.5 * patient has signed written informed consent prior to any study specific procedures. exclusion criteria: * patient is considered at high-risk for rf ablation due to major co-morbid medical conditions * patient has more than 3 tumors / lung * patient has at least one tumor \> 6 cm in greatest diameter * tumor is associated with atelectasis or obstructive pneumonitis * patient has renal failure requiring hemodialysis or peritoneal dialysis * patient has active clinically serious infection * patient has history of organ allograft * patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results * patient is pregnant or breast-feeding * patient has ecog performance status \> 2 * patient has platelet count ≤ 100 x 109 /l or international normalized ratio \> 1.5.

Keywords: radiofrequency ablation
nomogram to predict breast cancer related lymphedema

Conditions: Breast Cancer; Axillary Lymph Node Dissection; Breast Cancer Related Lymphedema; Axillary Reverse Mapping

Summary: it has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (alnd). however, the majority of breast cancer patients with complete alnd has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. with the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function. this arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. the arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older with t1-3 invasive breast cancer; * clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast; * patients who underwent mastectomy with a positive sentinel lymph node (sln); * patients who underwent breast-conserving surgery containing more than two positive slns. exclusion criteria: * neoadjuvant chemotherapy; * previous history of breast cancer.
the danish national survey of diet and physical activity 2021-2024

Conditions: Diet Habit; Nutritional and Metabolic Disease; Lifestyle

Summary: the danish national survey of diet and physical activity (dansda) 2021-23 is a nationally representative, cross-sectional survey of dietary and physical activity habits of 4-80 year-old danes, and is carried out at the national food institute, technical university of denmark (dtu food). dansda provides high quality, nationally representative data on diet, physical activity, smoking, alcohol and weight status in denmark.

the principal objective of dansda is to monitor dietary intake and physical activity in a representative sample of the danish population aged 4-80 years, and provide data for surveillance of the food and nutrient intake and physical activity of the general population. the survey is a nationally representative cross-sectional survey, which includes face-to-face interviews, anthropometric measurements, blood pressure measurement, blood sampling, 7-day web-based food diaries, and pedometer-determined physical activity which is recorded in 7-day web-based step diaries. in the interview socio-demographic details as well as lifestyle and health attitudes are recorded. web-based food and step diaries are collected in the entire survey population of 4000 individuals, blood pressure is measured in 15-80 year-olds, and biological samples (blood) are collected in a subpopulation of approximately 1000 individuals aged 40-70 years. biomarker of metabolic health are measured in a blood sample drawn after an overnight fast. the blood-based biomarkers (cholesterol, triglycerides, glucose), anthropometric data and blood pressure measurements are used to assess the prevalence of the metabolic syndrome (who definition) in 40-70 year-old danes. surplus blood samples are stored in a biobank for 30 years. the data from the survey provide the evidence base to support work by the authorities to facilitate the adoption of healthier eating and physical activity behavior and reduce lifestyle-related diseases. another objective is to provide detailed data on food consumption at the individual level, which enables food chemical exposure assessment and forms an essential part of food safety risk assessment. furthermore, the data will be used to assess the environmental impact of the diet.

Eligibility criteria:
inclusion criteria: * danish citizen * 4-80 years old * sufficient danish language proficiency exclusion criteria: * care home resident

Keywords: diet nutrition physical activity lifestyle metabolic syndrome anthropometrics blood pressure pedometer-determined steps bmi waist circumference metabolic health biomarkers
psychiatric inpatient discharge data - rwanda

Conditions: Mental Disorder

Summary: the aim is to provide a comprehensive assessment regarding the service provision and the accessibility to intensive mental health care in rwanda

for a one-year period, descriptive data on all inpatients with age \> 18 years, discharged from ndera hospital the only inpatient psychiatric hospital in rwanda, will be collected from files. the descriptive data includes diagnosis, duration of hospitalization, medication, addiction, insurance, somatic- and psychiatric comorbidity, referral pathways, employment status, number of previous hospitalizations. to the investigators' knowledge, there is no descriptive data on psychiatric inpatients in the country of rwanda. therefore, this. information will be crucial for understanding the service provision at the referral hospitals and the accessibility to intensive mental health care in rwanda. the data will be anonymized and recorded - this ensures the data cannot be linked to anyone subject which supplied it.

Eligibility criteria:
inclusion criteria: * all patients discharged from the inpatient psychiatric unit at ndera hospital, rwanda exclusion criteria: * none
pain and anxiety control during traditional mandibular anesthesia in children using distracting tools

Conditions: Inferior Alveolar Nerve Block

Summary: the aim of this study is to evaluate the effectiveness of two different audiovisual distraction techniques (audio video eyeglasses "vr box"/ tablet) in the management of anxious pediatric patients during inferior alveolar nerve block group a (control group): ian will be administrated with basic behavior guidance techniques and without using any type of distraction aids. group b: ian will be administrated with using av eyeglasses "vr box" and wireless headphone. group c: ian will be administrated with using tablet device and wireless headphone all of the children who experienced an inferior alveolar block with/without distraction will be assessed by using a combination of measures: wong-baker faces (self-report), pulse rate (physiological) and behavior (using flacc behavior rating scale "external evaluator

this study will evaluate the effectiveness of two types of distraction aids that contain video using (tablet device or vr box eyeglasses) and audio distraction using wireless headphone. pain and anxiety will be evaluated during inferior alveolar nerve block using three behavioral scales, wong-baker faces (self-report), pulse rate (physiological) and behavior (using flacc behavior rating scale "external evaluator". the first measure of heart pulse rate will be recorded directly when the patient seated comfortably on the dental chair, after anesthesia, the second heart pulse rate will be taken and the child patients will ask to choose a face that describe their status from one of the wong baker faces scale. for each child patient, all of the body responses will be recorded during the whole procedure and then will be evaluated by an external assessor to determine the children behavioral score according to flacc scale.

Eligibility criteria:
inclusion criteria: 1. age between 6 and 10 years. 2. no previous dental experience. 3. definitely positive or positive ratings of frank scale. 4. need of ian block for any dental treatment. exclusion criteria: 1. previous dental experience 2. systematic or mental disorders. 3. definitely negative or negative ratings of frankel scale 4. any contraindication for regional anesthesia
impact of zinc as a new adjuvant therapy for cow milk protein allergy in children.

Conditions: Cow Milk Protein Allergy

Summary: children presented with manifestations of cow milk protein allergy will be enrolled for cow milk -related symptoms score (comiss assessment). detailed history, nutritional and clinical examination will be done to fulfill items of comiss. children will be randomly allocated to two groups. oral zinc will be supplemented to the interventional group. comiss will be recorded at the baseline and weekly till 4 weeks. then oral food challenge (ofc) will be done to confirm the diagnosis and comiss assessment will be recorded again to see if zinc has any modulatory effect on reappearance of symptoms. the people administering the intervention, the people assessing the outcomes, the patients and their caregivers will all be blinded to the type of treatment. children who will be presented with skin manifestation will be assessed by severity scoring of atopic dermatitis index (scorad score) once diagnosed and weekly till 4 weeks after zinc supplementation to see if zinc has any modulatory effect.

children who will be presented with manifestations of cow milk protein allergy will be enrolled in the study for cow milk -related symptoms score (comiss) assessment. detailed history, nutritional and clinical examination will be done to fulfill items of comiss including skin manifestations as eczema , respiratory manifestations, git manifestations as constipation or diarrhea including bristol scale and regurgitations and duration of crying . children will be randomly allocated to two groups. randomization will be done using graphpad quickcalcs software to allocate into either the interventional or control group. oral zinc will be supplemented to the interventional group on adose of 30 mg elemental zinc/day. comiss will be recorded at the baseline and weekly till 4 weeks. then oral food challenge (ofc) will be done to confirm the diagnosis and comiss assessment will be recorded againto see if zinc has any modulatory effect on reappearance of symptoms. the people administering the intervention, the people assessing the outcomes, the patients and their caregivers will all be blinded to the type of treatment. children who will be presented with skin manifestation will be assessed by severity scoring of atopic dermatitis index (scorad score) once diagnosed and weekly till 4 weeks after zinc supplementation to see if zinc has any modulatory effect.

Eligibility criteria:
inclusion criteria: children suspected to have cow milk protein allergy using cow's milk-relatedsymptoms score with a score more than12 age less than 12 years old both sexes whose parents approved to be enrolled in the study exclusion criteria: children with comorbidities that may affect the duration of treatment as dysphagia. history of severe allergic reaction that required hospital admission as ora food challenge is expectedto be delayed in these patients. -multiple food allergies

Keywords: zinc cow milk protein allergy comiss scorad
topical insulin for postoperative wound healing

Conditions: Wound Complication; Insulin Resistance, Diabetes

Summary: this study aimed to investigate the potential effect of applying topical insulin therapy on the management and healing of postoperative wounds in patients known with type 2 diabetes mellitus (t2dm) and in a parallel group without diabetes. investigators also studied the effect of topical insulin therapy on the expression of e-cadherin and ki67, as markers for cellular proliferation and wound repair. the levels of il-6 and the h2o2-induced dna damage product, 8-hydroxy-2'-deoxyguanosine (8-ohdg), were assessed as markers for inflammation and oxidative stress. finally, histomorphological assessment of skin biopsies was also carried out.

the study participants will be recruited from general surgery department ,all patients with elective surgical procedure who will be admitted at the department for at least one week as it is the minimal duration of postoperative wound healing and the study will be conducted according to the regulations of ethical committee of clinical studies in the faculty of medicine, cairo university

Eligibility criteria:
inclusion criteria: * both males and females * 40-60 years old * diagnosed with type 2 dm (for the diabetic trial) * for the diabetic trial: glycosylated hemoglobin (hba1c) ≤7.5 % * haemoglobin (hb) ≥ 12 g/dl * patients who had a full thickness post-operative wound of ≥10 cm exclusion criteria: * those with known history of immunodeficiency, keloid formation, or hyperkeratotic skin lesion. * patients who had hypersensitivity to insulin, * patients with severe infection, * patients with any severe organ dysfunction * patients who were admitted to icu
lenvatinib plus vic-1911 in lenvatinib-unresponsive or lenvatinib-resistant hcc

Conditions: Liver Cancer; Hepatocellular Carcinoma; Resistant Cancer

Summary: this is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with aurora kinase a inhibitor vic-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(hcc).


Eligibility criteria:
inclusion criteria: (1) unlimited gender, aged 18-75 years; (2) meets american association for the study of liver diseases (aasld) or european association for the study of the liver (easl) clinical diagnostic criteria of hepatocellular carcinoma; (3) barcelona clinic liver cancer (bclc) stage c, and there is at least one measurable tumor in the liver (long diameter ≥ 1cm);(4) lenvatinib unresponsive or lenvatinib resistant after standard treatment; (5) child-pugh a or scored 7 b; (6) eastern cooperative oncology group performance status score \ = 60x10\^9/l, prothrombin time prolonged \<= 6 seconds. exclusion criteria: (1) uncorrectable coagulopathy with obvious bleeding tendency; (2) patients need long-term anticoagulant or anti platelet therapy and cannot stop the drugs; (3) patients with unstable or active ulcer or gastrointestinal bleeding; (4) heart disease requiring treatment or not well controlled high blood pressure; (5) hepatic encephalopathy or refractory ascites requiring treatment; (6) there is a clear active infection; (7) receiving radiotherapy/chemotherapy/interventional therapy for tumor within 4 weeks before the start of the study; (8) severe insufficiency of important organs, such as severe cardiopulmonary insufficiency; (9) other accompanying anti-tumor treatments; (10) the investigator assessed that the patient was unable or unwilling to comply with the protocol.

Keywords: aurora a kinase inhibitor
the effect of reflective breathing therapy compared with conventional breathing therapy in patients with chronic obstructive pulmonary disease (copd) iii-iv; part2

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine whether different types of breathing therapies in patients with copd iii-iv decrease dyspnea, increase activity and have impact on parasympathetic activities.


Eligibility criteria:
inclusion criteria: * inpatient rehabilitation * copd (gold stage iii and iv) exclusion criteria: * severe exacerbation in the last four weeks * acute infections * fever * neuritides * severe osteoporosis * skin disease * manic depression
modulation of plasmacytoid dendritic cell function in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.


Eligibility criteria:
inclusion criteria: * males and females, 18 to 60 year old, inclusive. * diagnosis of a relapsing form of multiple sclerosis as determined by revised mcdonald criteria or at least one clinical demyelinating episode with abnormal brain mri study based on champs criteria * expanded disability status scale (edss) score less than 6 at entry. * understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care. exclusion criteria: * treatment with corticosteroids within one month prior to the study. treatment with immunomodulatory drugs within last 3 months prior to the study. * no history of treatment with interferon-beta(ifn-beta) based drugs to exclude the possibility of ifn-beta neutralizing antibodies * any patient who is pregnant, intend to become pregnant, or breastfeeding at any time of the study. * history of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude ifn-beta therapy. * primary progressive multiple sclerosis patients or patients with secondary progressive multiple sclerosis with lack of recent clinical relapses for more than 2 years

Keywords: multiple sclerosis interferon beta plasmacytoid dendritic cells
assessing concentrations of methadone and its metabolites

Conditions: Opioid Use Disorder; Pain

Summary: an observational proof of concept method comparison study. comparing liquid chromatography -mass spectroscopy to a new quantitative lateral flow immunoassay with an optical reader.

cari health, inc.'s long-term goal is to address the problem of high dropout rates of patients receiving medication for opioid use disorder (moud; e.g., methadone) treatments, which has increased with the prevalence of fentanyl use, with an innovative point-of-care (poc) device to enable science-based personalized dosing for patients receiving methadone treatment for opioid use disorder (oud). the proposed solution consists of a customized analysis device that incorporates proprietary methadone detection technology for quickly measuring methadone and metabolite levels in the blood and calculating the methadone/metabolite ratio (mmr). to accomplish this long-term goal, the investigators aim to first quantitatively measure methadone doses taken and ethylidene-dimethyl-diphenyl pyrrolidine (eddp) detection using lateral flow assays. at this stage, the investigators are not testing a device. they are first assessing whether methadone metabolism can be evaluated using lateral flow assays, which are simple paper-based diagnostic strips. the tests work similarly to a home pregnancy test, where a sample (like blood, urine, or saliva) flows along a test strip and interacts with antibodies or other molecules that capture the target substance. no clinical decisions will be made, no treatment will be applied, and no dosing will be changed based on the results learned in this study.

Eligibility criteria:
inclusion criteria: age 18-70. a prescription for methadone at a dose of 10mg or more for at least 7 days. participants may be taking the methadone to treat an oud or for pain. taking methadone as prescribed during the last 4 days before consent to participate in the study. has been prescribed at least 1 day of take-home doses. exclusion criteria for methadone group includes: age \ 70. a condition preventing or complicating blood collection. conditions may include dermatological (skin) condition, bleeding diathesis, immunodeficiency, recent blood donation, anemia, end stage renal disease, liver cirrhosis, cancer, congestive heart failure, bleeding diathesis, tuberculosis (tb), active severe depression (e.g., suicidal ideation), or mania symptoms. tattoo or piercing close to sampling area. under a conservatorship.

Keywords: pharmacokinetics dose curve electrochemistry dose taken sensor personalized dosing pharmacogenomics
contribution of prf in cdh in children with prothetic patch closure

Conditions: Congenital Diaphragmatic Hernias

Summary: improved management of giant congenital diaphragmatic hernias (cdh) in neonates : decreased risk of morbidity and mortality due to prosthesis release. cdh is a rare disease with a still very dark prognosis, with a high rate of morbidity and mortality in giants forms linked to the release of insufficiently biologically integrated prosthesis. the biological functionalization of the prosthetic materials by host prf would improve the biological colonization of materials and thus reduce the risk of prosthetic release.


Eligibility criteria:
inclusion criteria: adult healthy volunteers : - over 18 years of age neonates: * aged between 1h of life and 28 days of life * born beyond 33 week of amenorrhea + 1day and 2kg of birth weight * hospitalized in the medical-surgical centre of pediatrics of the hospital of strasbourg * for whom a blood sample was prescribed as part of their routine care exclusion criteria: adult healthy volunteers : * systemic inflammatory disease * transient inflammatory state * any drug that modifies the coagulation cascade during the 48h preceding the sampling neonates: * risk of anemia \< 7g/dl * current anticoagulant treatment